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Leukemia chemotherapy is believed to be impeded by multidrug resistance (MDR). Some compounds of 
flavonoid molecules were previously shown to inhibit drug transporter Pgp or induce apoptosis to 
sensitize MDR tumors. In this study, we attempted to investigate the possibility and mechanism of 
quercetin and kaempferol, flavonoid molecules, in reversing MDR. K562/A cells were cultured in vitro 
with the flavonoids as single and in combination respectively. Cell growth inhibition and adriamycin 
(ADR) sensitivity were detected by 3-[4,5-dimethylthiazol-2-yl]-2,5 -diphenyltetrazolium bromide (MTT) 
assay. Cell apoptosis was examined by Annexin V/PI staining method. Moreover, the expression of 
related genes for drug transporters and apoptosis was also tested after incubation with resveratrol for 
the first time. Results show a dose dependent manner and synergistic effect of the two compounds on 
K562/A. Furthermore, some of the genes in drug transporter families such as ATP-binding cassette (ABC) 
and solute carrier (SLC) and apoptosis related genes such as Bcl-2、tumor necrosis factor (TNF) and 
tumor necrosis factor receptor (TNFR) families were regulated. The experiment indicates that quercetin 
and kaempferol may be used as reveratrol in leukemia chemotherapy, but their interaction and difference 
should be noticed. 
 





Chemotherapy is an important method for the treatment of 
leukemia, but seldom eradicates the disease. Alternative 
approaches including molecular targeting therapy, stem 
cell transplantation and antisense technology are also 
currently used. However, these therapies are usually 
complicated, and their effectiveness is even controversial 
for some cases. In addition, there therapies are very 
costly. 
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to chemotherapy in leukemia patients. MDR means 
leukemia cells resistant to one anti-leukemia drug become 
resistant to other drugs structurally and are mechanically 
different from the primary resistant drug. MDR can be 
primary (primary MDR), or secondary to the adminis- 
tration of an anti-leukemia drug (acquired MDR). The 
presence of MDR results in transient efficacies of 
anti-leukemia drugs, and rigorously limits the clinical use 
of chemotherapy. Many efforts have been focused on the 
research of MDR. For example, verapamil and cyclo- 
sporine A are useful for the reversion of MDR, but their 
accompanied side-effects and negative interactions with 
other anti-leukemia drugs limit their clinical use. 
Flavonoids are a variety of  natural  compounds  with  
 










similar molecular structures, which are present in berries 
and many other plants. About 6500 kinds of flavonoids 
have been described to date (Morris and Zhang, 2006). 
Based on their chemical structures, they can be classified 
as 15 subgroups including flavone, flavonol, flavonones, 
flavanonol, anthocyanidins, flavan-3,4-diols, xanthones, 
chalcones and biflavonoids, etc (Zhang et al., 2008). 
Natural flavonoids have significant pharmacological 
activities on tumors, cardiovascular system and endocrine 
system. In vitro studies have found that flavonoids have 
direct or indirect antitumor actions through interference of 
cell growth, inhibition of protein kinase activity, induction 
of apoptosis, suppression of matrix metalloproteinases 
secretion, and changes of tumor cell invasive behavior (Di 
Carlo et al., 1999). The antitumor activities of some 
flavonoids have also been confirmed in animal models 
(Mertens-Talcott, 2005) 
Many studies have revealed that flavonoids, especially 
flavones and flavonols, exhibit cytotoxicity specifically 
towards cancer cells through inducing cell cycle arrest 
and apoptosis (Limtrakul et al., 2007). Some flavonoids 
could reverse MDR through increase of intracellular 
antitumor drug concentration by inhibiting the important 
drug transporter Pgp on cell membrane (Marilyn and 
Zhang, 2006; Marks et al., 1992). Quercetin (Que) and 
kaempferol (Kae) are flavonoids extracted and separated 
from Choerospondiatis, a kind of Chinese herbal medicine 
grown in North China and widely used in cardiovascular 
disease. Flavonoids are considered to be its effective 
components. In this study, we applied Que and Kae 
(Figure 1) to the adriamycin-resistant variant human 
K562/A cells, in order to find out the mechanism of MDR 
reversion and the targets useful for the management of 
MDR, we observed the changes of cell growth rate, 
increase of their sensitivity to adriamycin (ADR), 
apoptosis, and the expression changes of drug 
transporter and apoptosis related genes. 
 
 




Human myelogenous leukemia K562 cells and the adriamycin- 
resistant variant K562/A cells (provided by Hematology Laboratory, 
Peking University First Hospital) were cultured in Iscove’s Modified 






with 10% fetal calf serum (Hyclone, USA) at 37°C in a humidified 
atmosphere of 95% air and 5% CO2. K562/A cells were cultured in a 
medium containing 1 µg/ml ADR (Main Luck Pharmaceutical, 
Shenzhen, China), and were grown in drug-free medium for two 
weeks before the experiments. 
 
 
Growth rate and ADR sensitivity evaluated by MTT assay 
 
K562 or K562/A cells in an amount of 2×10
4
/100 µl/well were 
cultured in 96-well plates (Corning, USA), and then cultured in a 
media containing various concentrations of drugs. The inhibition of 
cell growth rate was evaluated in cells treated with Que, Kae, or 
Que+Kae (National institute for the Control of Pharmaceutical and 
Biological Products, China) at the concentrations of 5 to 160 µmol/L. 
The changes of sensitivity to ADR were tested in cells treated with 
various concentrations of ADR, in combination with various 
concentrations of Que, Kae or Que+Kae. The experiments were 
also performed in cells treated with various concentrations of ADR, 
verapamil, and ADR+verapamil as test controls. After treatment for 
48 h, 10 µl of 5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5 
-diphenyltetrazolium bromide (MTT) (Sigma, USA) was added to 
each well, and the cells were incubated for another 4 h. MTT 
product was solubilized by addition of 150 µl/well DMSO, and 
measured at 570 nm using an ELISA reader (Thermo, USA). The 
experiment was performed in triplicate. IC50 (concentration required 




Apoptosis determined by annexin V/PI analysis 
 
For apoptosis measurement, K562 and K562/A cells were cultured 
in media containing various concentrations of Que, Kae, and 
Que+Kae for 72 h. Apoptosis of treated cells was measured by flow 
cytometry, using FITC-conjugated annexin V antibody and 
propidium iodide (KeyGen, China) following the manufacturer’s 
instructions. The experiment was repeated in triplicate. 
 
 
Gene expression determined by PCR array 
 
K562/A cells were treated with 20 µmol/L Que, Kae, and Que+Kae 
for 72 h. Total RNA was extracted from the treated cells using 
TRIZOL Reagent (Invitrogen, USA). Extracted total RNA was further 
purified by RNeasy MinElute Cleanup Kit (Qiagen, Germany). Its 
concentration and purity was determined by the NanoDrop ND-1000. 
Its integrity was checked by electrophoresis in a 1.2% agarose gel, 
and then it was reverse-transcribed by SuperScript III reverse 
transcriptase (Invitrogen, USA). The first strand cDNA was diluted 
and mixed with 2 X SuperArray PCR master mix and water to a total 
volume of 1100 µl, and the mixture was added to the Human Drug 
Transporters PCR Array or Apoptosis PCR Array (Superarray, USA). 
The array was placed in a quantitative real-time PCR instrument 
(ABI PRISM 7900 system, Applied Biosystems, USA), using a 
thermal cycle of 95°C for 10 min, 40 cycles of 95°C for 15 s and 
60°C for 1 min. The expression difference of a gene was calculated 





Data was expressed as mean ± SD, and analyzed with student t test 
by SPSS 17.0 software. P-value below 0.05 was considered as 
statistically significant. All data points were reported as the mean of 
triplicates. 






Que and Kae inhibited the growth of K562 and K562/A 
cells 
 
K562 and K562/A cells were cultured in various 
concentrations of ADR. The calculated ADR IC50 was 
1.48±0.34 µmol/L for K562 cells, and 76.82±4.14 µmol/L 
for K562/A cells. It can be seen that the ADR IC50 was 
51.9 times higher for K562/A cells than for K562 cells. 
Que and Kae inhibited the growth of K562 and K562/A 
cells in a dose-dependent manner, and the two flavonoids 
were synergistic in inhibition of the two cell lines (Figure 2). 
Verapamil in the concentration range of 5 to 20 µmol/L 
showed no significant inhibition effect on the growth of the 
two cell lines. 
 
 
Que and Kae increased the sensitivity of ADR on 
K562 and K562/A cells 
 
When K562 and K562/A cells were incubated in media 
containing lower concentration ADR (cell growth inhibition 
rate <15%), the addition of Que and/or Kae to the media 
resulted in the increase of their sensitivity to ADR, 
especially in K562/A cells. Que and/or Kae induced the 
increase of sensitivity to ADR in K562/A cells at a 
concentration as low as 10 µmol/L and in a concentration 
dependent manner. The two compounds had similar effect 
on the sensitivity to ADR when they were used at lower 
and moderate concentrations (P >0.05), but Que was 
more effective than Kae when they were used at higher 
concentrations (P <0.05). The two compounds had a 
synergetic effect when both of them were applied to the 
cells. When the effect of Que and Kae on the sensitivity to 
ADR was compared with that of verapamil, they were less 
effective when they were used separately at 10 µmol/L, 
but were more effective when they were used together 
even at lower concentrations (5 µmol/L). Therefore, Que 
and Kae enhanced the antitumor effect of chemo- 
therapeutic agents, especially when they were used 
together (Table 1). 
 
 
Que and Kae induced apoptosis 
 
Both Que and Kae induced apoptosis in K562 and K562/A 
cells. Apoptosis induced by Que, Kae, and Que+Kae was 
mainly found to be at early stage, and was in a dose- 
dependent manner. Que and Kae had similar effect on 
apoptosis of K562 and K562/A cells, and Que+Kae 
treatment seemed to be more active in inducing apoptosis 
than Que treatment and Kae treatment alone (Figure 3). 
In addition, verapamil had no apoptosis of the two cell 
lines, suggesting the different mechanism of MDR 
reversion between verapamil and the two flavonoids. 
 






Figure 2. Que and Kae inhibited the growth of K562 and K562/A cells in dose dependent manners. K562 (panel A) 
and K562/A (panel B) cells were cultured in media containing various concentrations (5 to 160 µmol/L) of Que, Kae, 
or Que+Kae, and in medium without any drugs as a negative control for 48 h. Living cells were measured by MTT 
method. Cell growth inhibition rate on ordinate was determined from MTT assay data using the formula: 
(1-absorbance of experiment group/absorbance of control group) × 100%. Data were presented as mean ± SD of 




Table 1. Increase of intracellular ADR in K562 and K562/A cells treated with various concentrations of Que and/or Kae. 
 
Group 
ADR IC50 (µmol/L) Increase of intracellular ADR (fold) 
K562 K562/A K562 K562/A 





 2.39 3.50 




 1.40 1.53 




 1.51 2.37 




 1.74 3.73 




 1.01 1.46 
Kae mid(20 µmol/L) 1.31±0.50 46.66±4.51
b▲▲
 1.13 1.65 
Kae high(40 µmol/L) 1.18±0.39 30.03±3.90
b
 1.25 2.56 




 1.10 3.99 




 2.74 5.48 




 3.08 5.97 
 
a 
P<0.05 VS control; 
b 
P<0.01 VS control; 
▲ 
P<0.05 VS verapamil; 
▲▲ 
P<0.01 VS verapamil. 
 






Figure 3. Apoptosis of K562 and K562/A cells induced by Que and/or Kae. Cultured K562 (panel A) or K562/A (panel B) cells 
(2×10
5
/ml/well) were treated with 10 µmol/L Kae (Kae low), 20 µmol/L Kae (Kae mid), 40 µmol/L Kae (Kae high), 10 µmol/L 
Que (Que low), 20 µmol/L Que (Que mid), 40 µmol/L Que (Que high), 5 µmol/L/each Que+Kae (Que+Kae low), 10 
µmol/L/each Que+Kae (Que+Kae mid) or 20 µmol/L/each Que+Kae (Que+Kae high) for 72 h; cells were cultured in medium 
without any drugs as a negative control and then cell apoptosis was examined by flow cytometry using Annexin V-FITC/PI 




The Apoptosis PCR array profiles the expression of key 
genes involved in apoptosis. The array includes TNF 
ligands and their receptors; members of the Bcl-2 family, 
caspase, nhibitor of apoptosis (IAP), TNF associated- 
factor (TRAF), Caring for Relatives with Dementia 
(CARD), death domain, death effector domain, and cell 
death-inducing DNA fragmentation factor-alpha-like 
effector (CIDE) families; as well as genes involved in p53 
and ataxia telangiectasia mutated (ATM) pathways. Que 
and Kae had different effect on genes related to apoptosis 
in K562/A cells. For example, Kae regulated the 
expression of 19 genes in all of the 84 genes on PCR 
array, but Que regulated only nine genes. Que and Kae 
down-regulated the expression of genes inhibited 
apoptosis such as Bcl-2, Bcl-w and up-regulated the 
expression of genes induced apoptosis such as BAD, and 
BIM in Bcl-2 family. Both of the flavonoids induced 
apoptosis though interfering with the balance of TNF and 
TNFR (Table 2). 
 
 
Que and Kae influenced the expression of drug 
transporter genes 
 
The Human Drug Transporters PCR array contains 84 
transporter genes. Transporters play key roles in 
pharmacological behaviors of drugs, affecting entry and 
extrusion of drugs in and out of cells. This array  includes  
 




Table 2. Expression changes of apoptosis related genes in K562/A cells treated with Que and Kae for 72h 
 
gene symbol                up or down regulation(fold)    gene description              
Que      Kae         
Bcl-2 family                                                                                                                    
BAD                          --        2.65                  Bcl-2-antagonist of cell death                      
Bcl-2                                            -3.16        -4.03         B-cell CLL/lymphoma 2,inhibition 
apoptosis        
BIM                               3.23    7.13           Bcl-2-like 11,apoptosis facilitator              
BCL-W                      --       -2.34          Bcl-2-like 2                               
BIK                             2.10           2.39            Bcl-2-interacting killer, apoptosis 
facilitator        
BNIP1                                            -- -2.50             Bcl-2/adenovirus E1B interacting protein 
1        
IAP family/card                                                                                                     
BIRC3                                          -3.60     -2.91                 Baculoviral IAP repeat-containing 3               
XIAP                                           --       -3.37                 X-linked inhibitor of apoptosis                  
TNF receptor                                                                                                      
CD40                                    2.53        2.62         TNF receptor super-family, member 5             
TNF RSF10A                          -6.03          -3.78          TNF receptor super-family, member 10a             
TNF RSF10B                     --          -3.50          TNFreceptorsuper-family, member 10b            
TNF RSF1A                       -2.54          -14.30               TNF receptor super-family, member 1A            
TNF RSF9                      -2.31          -2.08                TNF receptor super-family, member 9              
TNF Ligand Family                                                                                        
LTA                              --           3.53                TNF super-family, member 1                      
TNF                                      --      20.59         TNF super-family, member 2                   
Death Domain Family                                                                                         
DAPK1                            --     3.26                  Death associated protein kinase 1                 
p53 and DNA Damage  Response                                                                        
GADD45A                        2.02        7.08          Growth arrest and DNA damage 
inducible, alpha                                       
TP53 BP2                       --           2.39              Tumor protein p53 binding protein, 2               




transporters important to absorption, distribution, 
metabolism and excretion of many drugs. In addition, 
transporters such as ABC and SLC gene families which 
contribute to sensitivity and resistance of tumor cells are 
also included in this array. Que and Kae regulated some 
of the genes in ABC transporter family, such as down- 
regulating the famous drug resistance gene ABCB1 
(multidrug resistance1). The flavonoids also down- 
regulated the expression of genes relating to chemo- 
resistance in SLC family such as SLC28, SLC29, SLC7 





Our experiments revealed that the growth of K562 and 
K562/A cells was inhibited by Que and Kae, especially by 
Que, in a dose dependent manner, which are similar to 
the previous results reported by Chen et al. (2005) and 
Rusak et al.
 
(2005). An earlier study has also suggested 
the anti-proliferative activity of Que on normal bone 
marrow and leukemic progenitors through the interaction 
with type II estrogen binding sites (Larocca et al., 1991). 
We also found that Que and Kae were synergetic with 
ADR to enhance the antitumor efficiency of ADR, which 
indicate that Que and Kae have the ability to increase the 
sensitivity to chemotherapeutic agents such as ADR in 
addition to the inhibition of tumor cell growth. However, 
Kae may have specific ability in anti-proliferation. 
Bestwick et al. (2007) observed that Kae had cytotoxic 
potentials to HL-60 cells as low concentration as 1 µmol/L, 
which was probably related to induce cell membrane 
injury and apoptosis. They also found that Kae inhibited 
the growth of HL-60 cells at more than 10 µmol/L through 
changing cell cycles. 
MDR is a complicated phenomenon related to many 
processes. Membrane transporters play important roles in 
mediating chemo-sensitivity and drug resistance of tumor  
 




Table 3. Expression changes of drug transporter genes in K562/A cells treated with Que and Kae for 72 h. 
 
Gene symbol Substrate 
Up or down regulation (fold) 
Que Kae 
ABC Transporters 
ABCA13 Unknown - -4.75 
ABCA4 n-Retinylidiene-PE [10] -13.53 -11.20 
ABCB1 Anthracyclines, vinca alkaloids, imatinib [11] -10.03 -38.11 
ABCB11  Peptide[10] -3.94 -4.59 
ABCB4 Phosphatidylcholine [10] 2.00 3.10 
ABCB6 Iron [10] -3.46 -3.34 
    
SLC Transporters 
SLC10A1 Bile acid [12] -86.33 -12.51 
SLC22A1 
Verapamil, acyclovir, imatinib, oxaliplatin 
[13] 
-6.22 -3.21 
SLC28A2 Nucleoside[14] -5.01 -2.80 
SLC28A3 Pyrimidine and purine nucleoside [11] -2.96 - 
SLC29A1 Purine and pyrimidine nucleosides [11] - -2.33 
SLC2A1 Glucose [15] -2.01 -2.55 
SLC2A2 Glucose [15] -2.31 - 
SLC2A3 Glucose [15] - -2.95 
SLC31A1 Copper [11] -2.37 -2.67 
SLC38A2 Amino acid [16] -3.46 -3.13 
SLC38A5 Amino acid [16] -2.37 -3.50 
SLC3A1 Amino acid [16] - -3.01 
SLC3A2 Amino acid [11] -3.79 -6.70 
SLC25A13 Citrin [17] - -2.43 
SLC7A11 Cystine, L-glutamate [11] - -4.13 
SLC7A5 Large neutral L-amino acids, BCH [11] -2.50 -4.63 
SLC7A8 Neutral and acidic amino acid [18] -2.06 -2.09 
SLCO1A2 Bile acids [19] - -3.02 
SLCO2B1 Steroid hormone conjugates [20] -2.08 - 
    
Other Transporters 
AQP1 Water [16] - 3.23 
AQP7 Water, glycerol, urea [11] -2.19 - 
ATP6V0C Unknown - -2.09 
ATP7A p-Chloromercuribenzoate [11] - -4.37 
ATP7B Copper [21] - -2.79 
 




cells. In addition to traditional ABC transporters which 
exclude cytotoxic drugs from cancer cells to lower their 
intracellular concentrations, SLC transporters increase 
chemo-sensitivity by uptaking hydrophilic drugs. 
Structurally, these drugs often resemble the natural 
substrates of the respective transporters. In particular, 
members of the SLC19 family (reduced folate carrier, 
RFC family), SLC28 and 29 families (CNT and ENT 
nucleoside transporters), SLC7A and 3A families (amino 
acid transporters) and SLC31A (CTR copper transporter 
family) are important determinants of chemosensitivity to 
anticancer drugs (Huang and Sadée, 2006). 
In our real-time PCR array results, most ABC trans- 
porters including the famous drug resistance gene ABCB1 
were down-regulated, but ABCB4 was up-regulated in 
K562/A cells after Que and Kae treatment. It may relate to 
the phenomenon that different transporters mediate 
different substrates’ transportation across cell membrane. 
For example, some nutrient transporters (glucose, amino 
acids, organic anions, and peptides) in SLC family may be  
 




up-regulated in chemo-resistant tumor cells because of 
increased energy and nutrition needs. Therefore, 
down-regulation of many gene members in SLC family by 
Que and Kae treatment may simply reflect the decreased 
nutrient uptake due to the growth inhibition of the tumor 
cells. 
The therapeutic activity of many antitumor drugs has 
been found to rely on the activation of apoptosis pathways 
in tumor cells, and abnormalities in apoptosis is another 
important factor leading to multidrug resistance. Our 
results suggest that Que and Kae induce apoptosis 
through the expression change of some genes in bcL-2, 
TNF, and IAP families. However, Que and Kae are 
different in inducing apoptosis, and they block cell cycles 
at different phases (Gordana et al., 2005;
 
Bestwick et al., 
2007; Kandaswami et al., 2005). In acute myelocytic 
leukemia patients, for example, Que induced apoptosis by 
change of TRAIL signal pathway and caspase-3 
expression (Mertens-Talcott, 2005; Kim et al., 2008; 
Liesveld et al., 2003). In contrast, Kae was less active 
than Que in cell growth inhibition and apoptosis, but was a 
potent reactive oxygen species scavenger in menadione- 
stressed cells (Gordana et al., 2005). Therefore, Kae may 
be useful for regulation of immunological function and 
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